




Visiting the AADAP Website An Online Demonstration

presented by

Tom Bell
U.S. Fish and Wildlife Service
Aquatic Animal Drug Approval Partnership Program
Bozeman, Montana




































































GENERAL NEWS

North Carolina State University holds Fish Health Management course: The class is to being held 12-14 October at the NC State Vet Medicine campus, Raleigh, NC. More...

CVM Issues Proposed Regulations on MUMS Indexing:

The second of a series of features of the Minor Use and Minor Species Animal Health Act of 2004, drug indexing, is one loser to being seemed. More...

CVM Names New Director of the Office of Minor Use and Minor Species (OMUMS): In preparation for Dr. Andy Beaulieu's January 2007 retirement as the Director of OMUMS, Dr. Burnadette Dunham has been named to assume Dr. Beaulieu's role. More...

2006 Drug Approval Coordination Workshop: This year's annual Workshop was held in La Crosse, Wisconsin on 1-2 August 2006. More... partnership-based program of national scope located in Bozeman, Montana. The mission of the AADAP Program is:

"Working with our partners to conserve, protect, and enhance the Nation's fishery resources by coordinating activities to obtain U.S. Food and Drug Administration (FDA) approval for drugs, chemicals, and therapeutants needed in aquaculture and fisheries management programs."

Public and private aquaculture in the United States has struggled for many years because of a severe shortage of FDA approved drugs and therapeutants for use in aquatic species. This situation has ieopardized the health and fitness of aquatic species held in captivity, many of which are key to restoration, recovery, and management activities by the FWS and its many partners. New aquatic animal drug approvals will benefit Federal, State, Tribal and private aquaculture programs alike throughout the United States.

The second of a series of features of the Minor Use and Minor Species Animal Health Act of 2004, drug indexing, is one step closer to being implemented

View Details

FLASH PLAYER 8 REQUIRED TO VIEW PORTIONS OF THIS SITE

CLICK HERE TO DOWNLOAD





Fact Sheet: Florfenicol INAD 10-697

for detailed information, see INAD study protocol, use link on the left

Browse other INAD Drugs	*	

The following links are specific to:

Drug summary & history

Drug forms to be completed

Generic examples of completed forms

INAD study protocol

Material Safety Data Sheet (MSDS)

Study Summaries

What's the status of this drug's approval

Print this drug fact sheet

Print all drug fact sheets

INAD signup form (Federal facilities)

INAD signup form (other facilities)

Information on EPA's National Pollutant Discharge Elimination System (NPDES) Permits

Objective/purpose:	Collect supportive and pivotal data needed to establish the effectiveness of florfenicol	
Objective/purpose.	to control mortality caused by certain bacterial diseases.	
Drug name:	Florfenicol (Aquaflor TM)	
Source of drug:	Schering-Plough Animal Health	
Address:	1095 Morris Avenue Union, NJ 07083-1982	
Contact:	Dr. Richard Endris Phone: 908-473-3133; Fax: 908-629-3654; email: richard.endris@spcorp.com	
Target pathogen(s):	Bacterial pathogens susceptible to florfenicol.	
Method of administration:	Medicated-feed treatment	
Treatment dosage:	10 milligrams florfenicol per kilogram fish body weight per day	
Treatment regimen:	10 days (consecutive)	
Withdrawal period:	21 days (all salmonids) 28 days (all non-salmonids) No withdrawal period is required for fish that are not susceptible to legal harvest for a period of 28 days post-treatment.	
Required test parameters:	Investigator must collect mortality data throughout the 5-day pre-treatment, treatment, and 21-day post-treatment period. Investigator should also report general fish behavior and any adverse effects relating to treatment.	
Limitations or restrictions on use:	Investigator must follow all instructions in the Study Protocol for INAD 10-697 regarding drug acquisition and handling, fish treatment and disposition, and data reporting requirements. Drug discharge must be in compliance with local NPDES permitting requirements.	
Required INAD fee:	\$400.00 per facility per year	
required little lee.		
AADAP contact for other information:	Ms. Bonnie Johnson, FWS - AADAP Phone: 406-587-9265 ext. 136 Fax: 406-582-0242 bonnie_johnson@fws.gov	